gemcitabine + capecitabine + bevacizumab

Gemcitabine + capecitabine + bevacizumab is a combination regimen used primarily in the treatment of advanced cancers such as pancreatic and biliary tract cancer. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU), which interferes with DNA synthesis by inhibiting thymidylate synthase. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis required for tumor growth[1][2][6]. This combination leverages cytotoxic effects on tumor cells from gemcitabine and capecitabine with the antiangiogenic effect of bevacizumab to enhance antitumor activity[1][2]. The regimen has been studied in phase II trials for advanced pancreatic cancer and other solid tumors[1][2][8].

Other names

GemCap + bevacizumab